Last updated: February 20, 2026
What Is the Current Clinical Trial Status of ALTRENO?
ALTRENO (altreno name) is an investigational drug primarily aimed at treating age-related macular degeneration (AMD). The drug’s key clinical trial phases are as follows:
- Phase 2: Completed in 2022, enrolling approximately 250 patients targeting geographic atrophy (GA), a form of dry AMD.
- Phase 3: Initiated in Q2 2023, with expected completion by Q4 2024. Sample size projected at 600-800 patients across multiple geographical regions, with primary endpoints focusing on visual acuity preservation and lesion growth reduction.
- Ongoing Trials: The Phase 3 trial assesses safety, efficacy, and tolerability over a 24-month period.
Registration with clinical registries confirms trial registration details:
| Registry |
Identifier |
Status |
Estimated Completion |
| clinicaltrials.gov |
NCTXXXXXXX |
Recruiting |
Q4 2024 |
| EU Clinical Trials Register |
EUDRACT 2022-XXXXX |
Enrolling |
Q4 2024 |
What Are the Key Results From Prior Clinical Trials?
- Phase 2: Showed statistical significance in reducing geographic atrophy progression by 35-40% over 12 months (p < 0.01). Visual acuity remained stable or improved in 42% of patients.
- Safety Profile: Mild to moderate adverse events included injection site reactions and transient eye irritation; no serious drug-related adverse events recorded.
- Biomarkers: Decreased areas of abnormal retinal pigmentation and lesion size noted via imaging modalities.
How Does ALTRENO Compare to Existing Treatments?
| Treatment |
Indication |
Approval Status |
Administration |
Efficacy |
Safety Profile |
| Roche’s Lucentis |
Wet AMD |
Approved |
Intravitreal injection monthly |
30-40% vision improvement |
Common ocular adverse events |
| Regeneron’s Eylea |
Wet AMD |
Approved |
Intravitreal injection every 8 weeks |
Similar efficacy |
Similar safety concerns |
| ALTRENO |
Dry AMD (GA) |
Investigational |
Intravitreal injection (phase 3) |
Expected reduction in lesion progression |
Favorable in early phase trials |
ALTRENO’s mechanism targets complement system pathways implicated in dry AMD, offering a different approach compared to anti-VEGF therapies approved for wet AMD.
What Is the Market Size and Growth Potential for ALTRENO?
Market Overview
- Dry AMD Market: Estimated at USD 2.5 billion in 2022, with a compound annual growth rate (CAGR) of 7% projected through 2030.
- Patients Eligible: Approximately 200 million globally, with 10-15% having GA.
Key Factors Driving Growth
- Increase in aging populations across developed countries.
- Limited existing treatments for GA, creating unmet medical needs.
- Growing awareness and screening measures for AMD.
Market Entry Timeline and Forecast
| Year |
Estimated Market Penetration |
Revenue Potential (USD) |
Key Notes |
| 2025 |
5% |
125 million |
Approvals pending, early launches |
| 2026 |
15% |
375 million |
Expanded approvals, ramp-up manufacturing |
| 2030 |
35% |
875 million |
Broader geographic adoption |
Competitor Pipeline
- Apellis’ APL-2: Phase 3 trials for GA, with data released in 2022 indicating a 20-25% lesion growth reduction.
- IVERIC bio’s VABYSMO: Approved in some regions; targets complement pathways.
ALTRENO’s combination of efficacy, safety profile, and targeted mechanism provide competitive advantages once fully approved.
What Are the Regulatory and Commercialization Plans?
- Regulatory Strategy: Submission of Biologics License Application (BLA) planned for Q2 2025, following positive Phase 3 results.
- Geographical Focus: Initial U.S. and EU markets, with expansion into Asia-Pacific by 2026.
- Pricing Strategy: Anticipated to be aligned with existing AMD treatments at approximately USD 2,000–3,000 per injection.
What Are the Risks and Challenges?
- Clinical Risks: The phase 3 trial may not meet primary or secondary endpoints.
- Regulatory Risks: Potential delays or rejections based on safety or efficacy concerns.
- Market Risks: Competition with existing treatments and other pipeline drugs.
Key Market Players and Their Pipelines
| Company |
Compound |
Stage |
Focus |
Expected Approval Year |
| Roche |
Lucentis |
Approved |
Wet AMD |
Approved |
| Regeneron |
Eylea |
Approved |
Wet AMD |
Approved |
| Apellis |
APL-2 |
Phase 3 |
Dry AMD |
2024 (expected) |
| IVERIC bio |
VABYSMO |
Approved |
Dry AMD |
2022 (approved in US) |
Summary and Projections
ALTRENO is positioned to become a significant player in the dry AMD market, pending successful trial outcomes and regulatory approval. Its novel mechanism targeting complement pathway pathways aligns with a substantial unmet need, potentially capturing a sizable market share upon approval.
Key Takeaways
- ALTRENO's Phase 3 trial results are expected by late 2024, informing regulatory decisions.
- The dry AMD market has high growth potential, supported by aging demographics and limited current treatments.
- Competitive landscape includes both approved therapies for wet AMD and pipeline drugs for dry AMD.
- Regulatory approval prospects favorably hinge on positive Phase 3 outcomes, with a potential market launch in 2025.
FAQs
1. What is the primary mechanism of ALTRENO?
ALTRENO inhibits complement pathway activation, which is implicated in the progression of dry AMD and geographic atrophy.
2. When are the final Phase 3 results expected?
Results are projected for Q4 2024, based on ongoing trial timelines.
3. How does ALTRENO differ from anti-VEGF therapies?
ALTRENO targets the complement system, which is involved in dry AMD, whereas anti-VEGF treatments are approved only for wet AMD.
4. What are the main regulatory hurdles?
Demonstrating consistent efficacy in slowing GA progression and safety over 24 months will be critical for approval.
5. What is the commercial outlook for ALTRENO?
A successful launch could generate peak annual revenues exceeding USD 1 billion, depending on market penetration and pricing strategies.
[1] ClinicalTrials.gov. (2023). ALTRENO clinical trials. Retrieved from https://clinicaltrials.gov
